HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Supplement Industry Oversight Among FDA Programs Targeted For $86M Budget Cut

This article was originally published in The Rose Sheet

Executive Summary

The first budget proposal by President Trump suggests research by FDA's National Center for Toxicological Research on food- and nutritional supplement-related issues will be curtailed as part of a $3m cut to the center's appropriation.

You may also be interested in...



Appropriators' Interest Could Point To FDA Supplement Programs Funding Boost

House appropriators' letter to FDA Commissioner Gottlieb suggests they are listening to dietary supplement industry concerns and may be considering a funding boost for the Office of Dietary Supplement Programs, says executive Mike Greene.

FSMA Re-inspection Fees MIA As Waiver Guidance Remains AWOL

FDA will bill supplement and conventional food product firms $248 per hour for re-inspections in the US and $285 per hour outside the country in fiscal 2018, but as it has since Congress passed FSMA, the agency will not collect re-inspection and mandatory recall fees.

OTC Monograph User Fees Up To $34M Floated In Senate Discussion Draft

Bulk of user fees would be raised through facility fees, under Sens. Isakson and Casey’s discussion draft, but there's little time to add the changes to FDA user fee reauthorization bills already moving in Congress.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

RS109268

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel